You are now leaving the United Therapeutics ASSIST website and moving to an external website independently operated and not managed by United Therapeutics, Inc.
If you do not wish to leave this site, click Cancel. Or click OK to continue.
Preferred Method of Contact *
*Indicates required field.
This Form is NOT intended to contact United Therapeutics Corporation’s Medical Information Department or to report suspected Adverse Events. In the event of either, please use the contact information below.
Medical Information: Call 1-877-522-2950 or send requests directly to: DrugInformation@unither.com. Adverse Events: To report a suspected adverse reaction (ADR) to United Therapeutics, please send ADR information to DrugSafety@unither.com, or by faxing the ADR information to 1-919-313-1297, or to report ADRs to the FDA, ADR information can be submitted at 1-800-FDA-1088 or www.fda.gov/medwatch.
Thank you for your interest.
We will be in contact with you soon in regard to this inquiry.
Thank you for your interest in prescribing Remodulin® (treprostinil) injection. This referral form has recently been revised to include the Remunity® Pump for Remodulin, a new subcutaneous delivery pump option for your patients.
United Therapeutics is committed to ensuring the best experience for you and your patients through education and support. To learn more about the pump and considerations prior to prescribing, please request additional information or a visit from a representative using the form below.
Thank you, your request has been received. Please click below to continue to the PDF download.
iAssist allows healthcare providers (HCPs) to submit electronic prescriptions and referral forms, perform advanced benefit verifications, submit real-time electronic prior authorizations, obtain patient electronic consent, and track patient adherence to therapy through portal notifications.
Currently, the 48 mcg (112 ct) and 64 mcg (112 ct) Maintenance Kits (28-day supply) are available for ordering. These strengths correspond with 8-10 breaths and 11-12 breaths with the TYVASO nebulizer, respectively. The remaining Maintenance Kits and Titration Kits will be available soon.
To learn more about TYVASO DPI and Kit availability, please reach out to your local United Therapeutics Cardiopulmonary Specialist.
Pulmonary Hypertension Association is a worldwide community of patients, caregivers, family members, and healthcare professionals whose mission is to extend and improve the lives of people with PAH.
PH Aware works for awareness and global engagement on behalf of families, caregivers, and healthcare professionals, and supports research efforts to find a cure for PAH.
The Scleroderma Foundation's three-fold mission is to provide support, education, and research. The foundation has 19 active chapters and 160 support groups across the country.
TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prostacyclin mimetics indicated for the treatment of:
Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with TYVASO establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with TYVASO was limited to 12 weeks in duration.
WARNINGS AND PRECAUTIONS
DRUG INTERACTIONS/SPECIFIC POPULATIONS
Pulmonary Arterial Hypertension (WHO Group 1)
In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.
In a 3-week, open-label, single-sequence, safety and tolerability study (BREEZE) conducted in 51 patients on stable doses of TYVASO who switched to a corresponding dose of TYVASO DPI, the most commonly reported adverse events seen with TYVASO DPI in ≥4% of PAH patients during the 3-week treatment phase included cough (35.3%), headache (15.7%), dyspnea (7.8%), and nausea (5.9%).
Pulmonary Hypertension Associated with ILD (WHO Group 3)
In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions with TYVASO were similar to the experience in studies of PAH.
Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI™ Inhalation Powder, and additional information at www.TYVASOHCP.com or call 1-877-UNITHER (1-877-864-8437).
All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.
© 2022 United Therapeutics Corporation. All rights reserved.